GSK South Africa

“Our global quest is to improve the quality of human life by enabling people to do more, feel better and live longer” GlaxoSmithKline Mission...

GSK Biologicals: 2005 Global Business > £1,196 billion % growth > 50% US and Europe Infants Infanrix Every Second: 45 doses of vaccines delivered N°1 Provider 23% world Market Share (2004)

GSK Biologicals: Contributing to World Health  We are a primary supplier to international organizations  We provide vaccines to developing world at preferential prices  We distributed approximately 90% of our vaccine doses to the developing world in 2006 –More than 1.5 billion doses of GSK vaccines were distributed worldwide  We work with policy-makers to establish vaccination policies and ensure vaccines are available to all

Worldwide Market Share of Vaccine Companies in 2005 Total Market: £ 5.2 billion Source: GSK Bio estimates based on analyst reports and company press release

Vaccine Development Long Lead Times and Big Investment - GSK Bio Core competencies Identify Antigens Produce Antigens Test in Animals Proof of Concept Phase IIIIFile x Registration x up to £5.5mup to £30m£250m-500m x x 3-5 yrs 2-3yrs 2-4 yrs  1 yr x Transfer Process to Manufacturing Build Facility II Research (Inc. Immunology) Preclinical Development (Inc. Formulation Science) Clinical Development (Inc Post Marketing Surveillance

GSK Bio Milestones Killed polio vaccine (Salk™ type: injectable) 1961 Live attenuated polio vaccine (Sabin™ type: oral) 1969 Rubella vaccineWORLD FIRST 1976 Thermostable measles vaccine WORLD FIRST 1984 Varicella vaccine WORLD FIRST 1986 Recombinant hepatitis B vaccine WORLD FIRST 1992 Hepatitis A vaccine WORLD FIRST 1992 Influenza vaccine (from SSW) 1994 Acellular pertussis vaccine (DTPa)

1996 Combined DTPw HBV ± HibWORLD FIRST 1996 Combined hepatitis A&B WORLD FIRST 1997 Combined DTPa/Hib and DTPa IPV WORLD FIRST 1997 Priorix 1998 Combined DTPa IPV Hib vaccine 1999 DTPa booster vaccine 2000 DTPa HBV IPV (PeNta) (EU)WORLD FIRST 2000 DTPa HBV IPV/ Hib (Hexa) 2000 Combined Hepatitis A & TyphoidWORLD FIRST 2002 DTPa HBV IPV (Pediarix) (US) 2003 Combined meningitis ACW 135 WORLD FIRST 2005Rotavirus vaccine launch in Mexico GSK Bio Milestones (cont’d)

Recent Launches In South Africa  Rotarix – vaccine to prevent Rota Virus GE –Launched 2006  Vaccinated about babies so far  Prevented about 1000 hospitalizations  Infanrix Hexa –Launched January 2007 –Six vaccines in one injection  DTPa  IPV  Hib  HB

Pipe line  HPV Candidate Vaccine Incidence in Africa Mortality in Africa

HPV  The main cause of Cervical Cancer is HPV  Globally types 16, 18, 45 and 31 together account for more than 80% of Cervical Cancer cases

HPV  Up to 80% of women will be infected by an HPV infection at some point in their lives  Following HPV infection, your body does not always develop immunity and is therefore not protected against future infections.

Screening  Screening is the only way to prevent pre-cancerous lesions or the early signs of Cervical Cancer making it easier to treat successfully. However screening cannot prevent the cause of Cervical Cancer

Thank you